Daniel Brocks, MD
Ophthalmology · Needham, MANPI 1174797468
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $305 of the $425 with a category attached, or 71.7%. 8 manufacturers reported payments, led by Tarsus Pharmaceuticals, Inc. at 34.9% of the total. 2025 is the largest year on record at $247, 7.5 times the $33 reported in 2019. That places this record below the midpoint for ophthalmology clinicians in MA, where the typical reported total is $853.
Across 10 payments — averaging $42.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Tarsus Pharmaceuticals, Inc.$148
- Thea Pharma Inc.$120
- Mallinckrodt Hospital Products Inc.$45
- AbbVie$31
- Sun Pharmaceutical Industries Inc.$24
- Bausch & Lomb Americas Inc.$23
- plus $33 from 2 others
Across 4 payments — averaging $15,429 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$62K
What the payments were for
- Food & beverage$30572%
- Education$12028%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Tarsus Pharmaceuticals, Inc. | 2 | $148 |
| Thea Pharma Inc. | 2 | $120 |
| Mallinckrodt Hospital Products Inc. | 1 | $45 |
| AbbVie | 1 | $31 |
| Sun Pharmaceutical Industries Inc. | 1 | $24 |
| Bausch & Lomb Americas Inc. | 1 | $23 |
| Dompe US, Inc. | 1 | $17 |
| Eyevance Pharmaceuticals LLC | 1 | $16 |
How this compares
$425 in reported general payments places this provider in the 35th percentile of 653 ophthalmology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MoxifloxacinMoxifloxacin Hcl | 15 | $435 |
| ErythromycinErythromycin Base | 25 | $274 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Needham
- Rishi SinghBoston$1.7M
- Peter ChangWaltham$992K
- Stephen AnesiWaltham$922K
- David LallySpringfield$328K
- Adam RogersBoston$316K
- Bonnie HendersonBoston$279K
- Mark LatinaReading$279K
- Dean EliottBoston$250K
- Jeremy KievalLexington$232K
- Mina FarahaniBoston$227K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.